AstraZeneca Delegation visited Tianjin University

On 29 August, 2007, AstraZeneca delegation headed by Dr. David Haywood, Vice President of GPR&D, visited Tianjin University (TU). Vice President SHU Gequn met the guests in VIP room. VP SHU welcomed Dr. Haywood and his colleagues, and gave a brief introduction of Tianjin University, especially its teaching and research strength in the area of engineering. He expressed that the cooperation between TU and AZ has promoted the international research collaboration of TU, and will also help to improve the research innovation capability of both sides. Dr. Haywood introduced AZ’s history, operation, research and its investment in China. Both sides reviewed the first stage collaboration in the area of crystallization, and expressed the hope to further the cooperation in more areas such as green chemistry, process safety and pharmacy. During the visit, the delegation visited some labs in School of Chemical Engineering as well as the Crystallization Center, and discussed on cooperation details with faculty concerned. As the world’s seventh-largest drug maker, AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. AstraZeneca has 7 major R&D centers located in 11 countries and was the first multinational pharmaceutical company to conduct large-scale international multi-center trials in China, and the first to establish a clinical research center.